ID16866A - Kompleks kompleks inklusi garam-garam aril-heterosiklik - Google Patents

Kompleks kompleks inklusi garam-garam aril-heterosiklik

Info

Publication number: ID16866A
Authority: ID; Indonesia
Prior art keywords: complex; heterosiclic; aryl; salt inclusion; inclusion
Prior art date: 1996-05-07

Application number

IDP971488A

Other languages

English (en)

Inventor

Kevin Charles Johnson

Yesook Kim

Ravi Mysore Shanker

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-07

Filing date

1997-05-05

Publication date

1997-11-20

1997-05-05 Application filed by Pfizer filed Critical Pfizer

1997-11-20 Publication of ID16866A publication Critical patent/ID16866A/id

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nanotechnology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pyridine Compounds (AREA)
Hydrogenated Pyridines (AREA)
Soil Conditioners And Soil-Stabilizing Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Seasonings (AREA)
Machine Translation (AREA)

IDP971488A 1996-05-07 1997-05-05 Kompleks kompleks inklusi garam-garam aril-heterosiklik ID16866A (id)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1920496P	1996-05-07	1996-05-07

Publications (1)

Publication Number	Publication Date
ID16866A true ID16866A (id)	1997-11-20

Family

ID=21791976

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IDP971488A ID16866A (id)	1996-05-07	1997-05-05	Kompleks kompleks inklusi garam-garam aril-heterosiklik

Country Status (47)

Country	Link
US (2)	US6232304B1 (id)
EP (1)	EP0900088B1 (id)
JP (1)	JP3579060B2 (id)
KR (1)	KR20000010823A (id)
CN (1)	CN1216923A (id)
AP (1)	AP796A (id)
AR (2)	AR007002A1 (id)
AT (1)	ATE257714T1 (id)
AU (1)	AU713711B2 (id)
BG (3)	BG64475B2 (id)
BR (1)	BR9709213A (id)
CA (1)	CA2251912C (id)
CO (1)	CO4600677A1 (id)
CZ (1)	CZ297847B6 (id)
DE (1)	DE69727218T2 (id)
DK (1)	DK0900088T3 (id)
DZ (1)	DZ2220A1 (id)
EA (1)	EA001731B1 (id)
EG (1)	EG24135A (id)
ES (1)	ES2212809T3 (id)
GE (1)	GEP20074185B (id)
GT (1)	GT199700044A (id)
HN (1)	HN1997000039A (id)
HR (1)	HRP970237B1 (id)
HU (1)	HU222451B1 (id)
ID (1)	ID16866A (id)
IL (1)	IL126546A (id)
IS (1)	IS2524B (id)
MA (1)	MA24172A1 (id)
ME (1)	ME00880B (id)
MY (1)	MY121999A (id)
NO (1)	NO324373B1 (id)
NZ (1)	NZ332220A (id)
OA (1)	OA10907A (id)
PL (1)	PL189324B1 (id)
PT (1)	PT900088E (id)
RS (1)	RS49532B (id)
SA (1)	SA97180024B1 (id)
SI (1)	SI0900088T1 (id)
SK (1)	SK282032B6 (id)
TN (1)	TNSN97075A1 (id)
TR (1)	TR199802231T2 (id)
TW (1)	TW514529B (id)
UA (1)	UA57734C2 (id)
UY (1)	UY24544A1 (id)
WO (1)	WO1997041896A2 (id)
ZA (1)	ZA973874B (id)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA57734C2 (uk) *	1996-05-07	2003-07-15	Пфайзер Інк.	Комплекси включення арилгетероциклічних солей
DE69730902T2 (de) *	1996-05-07	2006-02-23	Pfizer Inc.	Verfahren zur Selektion eines Salzes zur Herstellung eines Inklusionskomplexes
IL127497A (en) *	1997-12-18	2002-07-25	Pfizer Prod Inc	Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en)	1998-04-29	2004-03-16	Osi Pharmaceuticals, Inc.	N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) *	1998-11-02	2008-05-15	Elan Pharma International Limited	Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) *	1999-05-10	2010-07-14	栄研化学株式会社	ホタルルシフェリンの安定化方法
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en)	1999-11-11	2006-08-08	Osi Pharmaceuticals, Inc.	Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6884885B2 (en)	2000-12-21	2005-04-26	Cerestar Holding B.V.	Production of cyclodextrin complexes
US7034013B2 (en) *	2001-03-20	2006-04-25	Cydex, Inc.	Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) *	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040048876A1 (en) *	2002-02-20	2004-03-11	Pfizer Inc.	Ziprasidone composition and synthetic controls
US6869939B2 (en) *	2002-05-04	2005-03-22	Cydex, Inc.	Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
CN100335047C (zh)	2002-08-20	2007-09-05	布里斯托尔-迈尔斯斯奎布公司	阿立哌唑复合制剂和方法
AU2003263413A1 (en) *	2002-09-17	2004-04-08	Warner-Lambert Company Llc	Heterocyclic substituted piperazines for the treatment of schizophrenia
MXPA05002561A (es) *	2002-10-25	2005-05-05	Pfizer Prod Inc	Nuevas formulaciones de liberacion prolongada inyectables.
RU2292207C2 (ru) *	2002-10-25	2007-01-27	Пфайзер Продактс Инк.	Депо-препараты арилгетероциклических активных веществ в виде суспензии
EP1556086A2 (en) *	2002-10-31	2005-07-27	Pfizer Products Inc.	Solid and semi-solid polymeric ionic conjugates
WO2004039410A2 (en) *	2002-10-31	2004-05-13	Pfizer Products Inc.	Liquid conjugates of solid pharmaceuticals
EP1418492B1 (en) *	2002-11-05	2017-09-20	LG Electronics, Inc.	Touch screen mounting assembly for LCD monitor
CN1255105C (zh) *	2002-12-17	2006-05-10	上海医药工业研究院	齐拉西酮及其盐的水溶性包合物及其制备方法
WO2005016325A2 (en) *	2003-06-03	2005-02-24	Teva Pharmaceutical Industries Ltd.	CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
AR046811A1 (es) *	2003-09-02	2005-12-28	Imran Ahmed	Formas de dosificacion oral de ziprasidona de liberacion sostenida
MXPA06006291A (es) *	2003-12-08	2006-08-23	Univ Arizona	Composiciones anti-cancer sinergisticas.
WO2005065660A2 (en) *	2003-12-31	2005-07-21	Alpharma, Inc.	Ziprasidone formulations
SI21703A (en) *	2004-01-14	2005-08-31	Lek Farmacevtska Druzba Dd	Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
EP1744750A2 (en)	2004-05-06	2007-01-24	Sandoz AG	Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2006032957A1 (en) *	2004-05-26	2006-03-30	Pfizer Products Inc.	In vitro predictive method
US20070237828A1 (en) *	2004-06-11	2007-10-11	Dr. Reddy's Laboratories Limited	Ziprasidone Dosage Form
EP1827374B1 (en) *	2004-11-16	2014-11-05	Alkermes Pharma Ireland Limited	Injectable nanoparticulate olanzapine formulations
EP1863806A1 (en) *	2005-02-11	2007-12-12	Teva Pharmaceutical Industries Ltd	Amorphous ziprasidone mesylate
WO2006096462A1 (en) *	2005-03-03	2006-09-14	Elan Pharma International Limited	Nanoparticulate compositions of heterocyclic amide derivatives
WO2006099452A1 (en) *	2005-03-14	2006-09-21	Teva Pharmaceutical Industries Ltd.	Anhydrous ziprasidone mesylate and a process for its preparation
WO2006098834A2 (en) *	2005-03-14	2006-09-21	Teva Pharmaceutical Industries Ltd.	Crystalline forms of ziprasidone mesylate
US20070191306A1 (en) *	2005-08-17	2007-08-16	Bristol-Myers Squibb Company	FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en)	2006-10-02	2010-08-12	James Cloyd	Novel parenteral carbamazepine formulation
CN100391458C (zh) *	2006-02-07	2008-06-04	上海医药工业研究院	齐拉西酮或其盐包合物制备方法
DK2081921T3 (da)	2006-07-10	2011-01-03	Paion Uk Ltd	Korttidsvirkende benzodiazepinsalte og deres polymorfe former
MX2009011681A (es) *	2007-05-18	2009-11-10	Scidose Llc	Formulaciones de ziprasidona.
US8192721B2 (en) *	2007-12-13	2012-06-05	Verrow Pharmaceuticals, Inc.	Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) *	2008-05-09	2013-01-23	沈阳药科大学	桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
WO2011148253A2 (en)	2010-05-25	2011-12-01	Aurobindo Pharma Limited	Solid dosage forms of antipsychotics
EP2450039A1 (en)	2010-11-08	2012-05-09	PAION UK Ltd.	Dosing regimen for sedation with CNS 7056 (Remimazolam)
SI23610A (sl)	2011-01-13	2012-07-31	Diagen@d@o@o	Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) *	2011-05-25	2014-12-17	上海医药工业研究院	卢拉西酮组合物
TW201332572A (zh)	2011-12-28	2013-08-16	Otsuka Pharma Co Ltd	具有經取代的β－環糊精之藥物製劑
AR094963A1 (es)	2013-03-04	2015-09-09	Ono Pharmaceutical Co	Reacción de oxidación excelente en el índice de conversión
US20250049709A1 (en) *	2021-12-11	2025-02-13	Beloteca, Inc.	Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3459731A (en) *	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
IT1196033B (it)	1984-02-22	1988-11-10	Chiesi Farma Spa	Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es)	1987-03-02	1994-02-23	Pfizer	Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en)	1988-01-22	1989-11-28	Pfizer Inc.	Piperazinyl-heterocyclic compounds
US4831031A (en)	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1255462B (it)	1992-07-28	1995-11-02	Grazia Maffione	Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en)	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it)	1993-01-29	1996-09-04	Paolo Chiesi	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en)	1993-05-24	1995-09-28	Europharmaceuticals Sa	Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it)	1994-04-22	1997-04-08	Chiesi Farma Spa	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr)	1994-06-16	1996-04-02	Europharmaceuticals Sa	Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
UA57734C2 (uk) *	1996-05-07	2003-07-15	Пфайзер Інк.	Комплекси включення арилгетероциклічних солей
TW491847B (en)	1996-05-07	2002-06-21	Pfizer	Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
DE69730902T2 (de)	1996-05-07	2006-02-23	Pfizer Inc.	Verfahren zur Selektion eines Salzes zur Herstellung eines Inklusionskomplexes
JP3102896B2 (ja)	1996-05-07	2000-10-23	ファイザーインク．	５―（２―（４―（１，２―ベンズイソチアゾール―３―イル）―１―ピペラジニル）エチル）―６―クロロ―１，３―ジヒドロ―２（１ｈ）―インドール―２―オン（＝ジプラシドン）のメシレート三水和物、その調製法およびドーパミンｄ２アンタゴニストとしてのその使用
JPH10194996A (ja) *	1996-12-25	1998-07-28	Janssen Pharmaceut Nv	アシル化シクロデキストリン含有製薬組成物

1997
- 1997-01-04 UA UA98105560A patent/UA57734C2/uk unknown
- 1997-03-25 TW TW086103749A patent/TW514529B/zh not_active IP Right Cessation
- 1997-04-01 EP EP97907246A patent/EP0900088B1/en not_active Expired - Lifetime
- 1997-04-01 IL IL12654697A patent/IL126546A/xx not_active IP Right Cessation
- 1997-04-01 DE DE1997627218 patent/DE69727218T2/de not_active Expired - Lifetime
- 1997-04-01 US US09/147,239 patent/US6232304B1/en not_active Expired - Lifetime
- 1997-04-01 KR KR1019980708959A patent/KR20000010823A/ko not_active Ceased
- 1997-04-01 SK SK1504-98A patent/SK282032B6/sk not_active IP Right Cessation
- 1997-04-01 CA CA002251912A patent/CA2251912C/en not_active Expired - Lifetime
- 1997-04-01 JP JP53966997A patent/JP3579060B2/ja not_active Expired - Lifetime
- 1997-04-01 TR TR1998/02231T patent/TR199802231T2/xx unknown
- 1997-04-01 AU AU19372/97A patent/AU713711B2/en not_active Expired
- 1997-04-01 HU HU9902799A patent/HU222451B1/hu active IP Right Grant
- 1997-04-01 SI SI9730623T patent/SI0900088T1/xx unknown
- 1997-04-01 ES ES97907246T patent/ES2212809T3/es not_active Expired - Lifetime
- 1997-04-01 BR BR9709213A patent/BR9709213A/pt not_active Application Discontinuation
- 1997-04-01 AT AT97907246T patent/ATE257714T1/de active
- 1997-04-01 ME MEP-1997-172A patent/ME00880B/me unknown
- 1997-04-01 NZ NZ332220A patent/NZ332220A/xx not_active IP Right Cessation
- 1997-04-01 DK DK97907246T patent/DK0900088T3/da active
- 1997-04-01 PT PT97907246T patent/PT900088E/pt unknown
- 1997-04-01 EA EA199800910A patent/EA001731B1/ru not_active IP Right Cessation
- 1997-04-01 CN CN97194242A patent/CN1216923A/zh active Pending
- 1997-04-01 WO PCT/IB1997/000321 patent/WO1997041896A2/en not_active Ceased
- 1997-04-01 PL PL97329928A patent/PL189324B1/pl unknown
- 1997-04-01 CZ CZ0346198A patent/CZ297847B6/cs not_active IP Right Cessation
- 1997-04-02 HN HN1997000039A patent/HN1997000039A/es unknown
- 1997-04-10 GT GT199700044A patent/GT199700044A/es unknown
- 1997-04-28 CO CO97022511A patent/CO4600677A1/es unknown
- 1997-04-30 AP APAP/P/1997/000977A patent/AP796A/en active
- 1997-05-04 EG EG37897A patent/EG24135A/xx active
- 1997-05-05 ID IDP971488A patent/ID16866A/id unknown
- 1997-05-05 AR ARP970101854A patent/AR007002A1/es active IP Right Grant
- 1997-05-06 MY MYPI97001984A patent/MY121999A/en unknown
- 1997-05-06 UY UY24544A patent/UY24544A1/es not_active IP Right Cessation
- 1997-05-06 TN TNTNSN97075A patent/TNSN97075A1/fr unknown
- 1997-05-06 RS YU17297A patent/RS49532B/sr unknown
- 1997-05-06 ZA ZA973874A patent/ZA973874B/xx unknown
- 1997-05-06 MA MA24596A patent/MA24172A1/fr unknown
- 1997-05-06 DZ DZ970067A patent/DZ2220A1/fr active
- 1997-05-07 HR HR970237A patent/HRP970237B1/xx not_active IP Right Cessation
- 1997-05-12 SA SA97180024A patent/SA97180024B1/ar unknown
1998
- 1998-10-27 IS IS4880A patent/IS2524B/is unknown
- 1998-10-30 OA OA9800204A patent/OA10907A/en unknown
- 1998-11-03 BG BG108606A patent/BG64475B2/bg unknown
- 1998-11-03 BG BG102894A patent/BG64474B1/bg unknown
- 1998-11-06 NO NO19985192A patent/NO324373B1/no not_active IP Right Cessation
2001
- 2001-05-07 US US09/850,658 patent/US6399777B2/en not_active Expired - Lifetime
2004
- 2004-02-25 BG BG108606A patent/BG64475B1/bg unknown
- 2004-08-27 AR ARP040103099A patent/AR045528A2/es not_active Application Discontinuation
2006
- 2006-12-13 GE GEAP20069762A patent/GEP20074185B/en unknown

Also Published As

Publication number	Publication date
BG64475B1 (bg)	2005-04-30
WO1997041896A3 (en)	1998-01-08
BR9709213A (pt)	1999-08-10
SK282032B6 (sk)	2001-10-08
AU713711B2 (en)	1999-12-09
EP0900088A2 (en)	1999-03-10
UY24544A1 (es)	2000-09-29
HRP970237A2 (en)	1998-12-31
JPH11509866A (ja)	1999-08-31
CO4600677A1 (es)	1998-05-08
TR199802231T2 (xx)	1999-02-22
AP9700977A0 (en)	1997-07-31
CA2251912A1 (en)	1997-11-13
HRP970237B1 (en)	2002-04-30
NO324373B1 (no)	2007-10-01
HUP9902799A3 (en)	2000-12-28
IS4880A (is)	1998-10-27
EA199800910A1 (ru)	1999-04-29
DZ2220A1 (fr)	2002-12-03
US20010031756A1 (en)	2001-10-18
NZ332220A (en)	2000-03-27
IL126546A0 (en)	1999-08-17
NO985192L (no)	1998-11-06
DE69727218D1 (de)	2004-02-19
OA10907A (en)	2001-10-26
EA001731B1 (ru)	2001-08-27
JP3579060B2 (ja)	2004-10-20
CZ297847B6 (cs)	2007-04-11
MY121999A (en)	2006-03-31
DK0900088T3 (da)	2004-04-19
ATE257714T1 (de)	2004-01-15
CN1216923A (zh)	1999-05-19
DE69727218T2 (de)	2004-11-18
GEP20074185B (en)	2007-08-10
EG24135A (en)	2008-08-06
UA57734C2 (uk)	2003-07-15
YU17297A (sh)	1999-12-27
AU1937297A (en)	1997-11-26
GT199700044A (es)	1998-10-02
PT900088E (pt)	2004-04-30
IL126546A (en)	2001-01-28
EP0900088B1 (en)	2004-01-14
HUP9902799A2 (hu)	1999-12-28
PL329928A1 (en)	1999-04-26
WO1997041896A2 (en)	1997-11-13
RS49532B (sr)	2006-12-15
MA24172A1 (fr)	1997-12-31
SI0900088T1 (en)	2004-04-30
CZ346198A3 (cs)	1999-09-15
SK150498A3 (en)	2000-01-18
SA97180024B1 (ar)	2005-12-24
PL189324B1 (pl)	2005-07-29
AR007002A1 (es)	1999-10-13
BG64474B1 (bg)	2005-04-30
TNSN97075A1 (fr)	2005-03-15
HN1997000039A (es)	1997-06-26
US6399777B2 (en)	2002-06-04
US6232304B1 (en)	2001-05-15
AR045528A2 (es)	2005-11-02
NO985192D0 (no)	1998-11-06
CA2251912C (en)	2003-06-03
KR20000010823A (ko)	2000-02-25
ES2212809T3 (es)	2004-08-01
TW514529B (en)	2002-12-21
AP796A (en)	1999-12-24
ZA973874B (en)	1998-11-06
IS2524B (is)	2009-07-15
HU222451B1 (hu)	2003-07-28
ME00880B (me)	2006-12-15
BG102894A (en)	1999-09-30
BG64475B2 (bg)	2005-04-30

Publication	Publication Date	Title
ID16866A (id)	1997-11-20	Kompleks kompleks inklusi garam-garam aril-heterosiklik
BR9507179A (pt)	1997-10-07	Derivados de 3-aril-4-hidróxi-delta3-dihidrotiofena
CY2012029I2 (el)	2015-08-05	Nεα μορφη της 5-ομεπραζολης
DK0901474T3 (da)	2006-07-31	Arylpyrimidinderivater
DK0891332T3 (da)	2004-07-05	6-phenylpyridyl-2-aminderivater
ID24829A (id)	2000-08-24	Garam natrium omeprazola
NO981946D0 (no)	1998-04-29	Imidazoquinazolin-derivater
PT927183E (pt)	2004-12-31	Inibidores espirociclicos de metaloproteases
DE69732576D1 (de)	2005-03-31	Tetrahydrobenzindolon-derivate
EE9900182A (et)	1999-12-15	2-metoksüfenüülpiperasiini derivaadid
ID18027A (id)	1998-02-19	Garam amina
NO995853L (no)	2000-01-31	Nytt salt
ID16838A (id)	1997-11-13	Komposisi dekafluoropentana
ID17419A (id)	1997-12-24	Komposisi dekafluoropentana
FI943921L (fi)	1996-02-27	Vapaan trypsinogeeni-2:n määritys
FI965181L (fi)	1998-06-21	Polyalkoholi-peptidijohdannaiset
DK0827503T3 (da)	2000-11-20	Pyrrolidinylmethylindol-salt
DE69709700D1 (de)	2002-02-21	Kontrastmittel
BR9704770A (pt)	1998-11-03	Derivados de 1-carba-(detia)-cefalosporina
FR2763940B1 (fr)	1999-08-27	Preparation de trifluoromethoxy-2-aniline
BR1100811A (pt)	2002-06-11	Derivados de 1-metil-carbapenema
UA25722A (uk)	1998-12-25	Формувач сиhхроhізоваhих імпульсів
UA644S (uk)	1994-12-29	Мікро-еом широкого призначення
KR960005231U (ko)	1996-02-16	염전용 개량물꼬
KR960009913U (ko)	1996-04-12	방수용 휴지걸이